In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.
Conduent
Conduent Insights Hub
- All
-
By Service
- By Service
- Business Process Solutions
- Document Management and Automation
- Casualty Claims Solutions
- Human Resource and Learning Solutions
- Finance, Accounting, and Procurement
- Financial Industry Solutions
- Legal, Compliance, and Analytics Solutions
- Customer Experience Management
- Customer Contact Services
- Multichannel Communications
- Work-at-Home Solutions
- Healthcare Solutions
- Payer Solutions
- Provider Solutions
- Pharma and Life Sciences Solutions
- Government Healthcare Solutions
- Payment and Eligibility Solutions
- Child Support Solutions
- Eligibility and Enrollment
- Federal and State Services
- Government Payment Solutions
- Transportation Solutions
- Public Safety
- Transit Solutions
- Curbside Management
- Road Usage Charging
- By Type
